What Travera does

Travera is a privately held, Cambridge/Medford, Massachusetts-based precision oncology company founded in 2017–2018 to commercialize the Suspended Microchannel Resonator (SMR) — a microelectromechanical systems (MEMS) device invented in the Manalis Lab at MIT — as a clinical Laboratory Developed Test (LDT). The SMR weighs individual live cancer cells ex vivo with precision better than one part in 1,000 (under 50 femtograms), detecting cell mass response to FDA-approved drugs within hours rather than waiting days or weeks for cell death. Travera packages this measurement through a five-step clinical workflow — cell purification, drug incubation, SMR mass-distribution measurement with AI-based brightfield image classification for impurity removal (~20,000-image training set), and p-value-based 0–100 drug-response scoring — delivered as a 2-day-turnaround CLIA-certified report to the ordering physician.

The company's commercial product line, branded Rapid Therapy Selection™ (RTS), is offered in two variants: Travera EarlyAccess™, a predetermined panel of up to 20 FDA-approved drugs for a flat $500 fee (requiring outcome-data sharing), and Travera RTS™, a custom panel at $1,000 per drug (up to $20,000 per full panel). All payments are out-of-pocket (no reimbursement during the Early Access Program), processed after physician order via phone, Jotform, or downloadable requisition form, with sample logistics handled through FedEx overnight to Travera's Medford, MA lab. The company also runs multi-site clinical studies (TRV-001, solid tumor sub-study, AML pilot, TRV-002, and TRV-003/TraveraRTGx with xCures) at Dana-Farber, MGH, Weill Cornell, Mount Sinai, City of Hope, Emory Winship, Sequoia/Dignity Health, and John B. Amos.

Travera targets late-stage, relapsed, or treatment-refractory cancer patients — and the oncologists who treat them — across 39 NCCN cancer indications plus an off-label panel (~90% of cancers), with 100+ FDA-approved drugs validated in its catalog. Distribution relies on physician-initiated orders, direct field sales (VP Business Development hired July 2022 from Agendia/Myriad), and partnerships with ~18 cancer patient advocacy organizations (Cancer Commons, METAvivor, GO2, PanCAN, etc.) that route patients toward participating oncologists. Cumulative disclosed funding is approximately $13.6M+ across a 2018 round ($8.4M), 2021 round ($4M), NSF SBIR awards, and 2023 MedTech Innovator selection.

Name

Travera

Legal name

Travera Inc.

Website

https://travera.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Travera is a privately held MIT-spinout precision oncology company operating a CLIA-certified Laboratory Developed Test that uses a proprietary Suspended Microchannel Resonator to measure live cancer cells' mass response to FDA-approved drugs, delivering 2-day personalized therapy guidance to oncologists treating late-stage cancer patients.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Functional precision oncology
• Cancer drug response testing
• Clinical laboratory diagnostics
• Ex vivo drug screening
• Cancer therapy selection

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Rapid Therapy Selection™ Test Sales (EarlyAccess and RTS): One-time per-order clinical laboratory testing fees paid out-of-pocket by patients. EarlyAccess: flat $500 for a predetermined panel of up to 20 FDA-approved drugs (requires patient to share treatment outcome data to build clinical evidence). RTS: $1,000 USD per drug for a custom panel of up to 20 drugs. Patients billed after the physician orders the test; payment via credit/debit card or e-check; HSA/FSA eligible. All expenses are out-of-pocket and not reimbursable during the Early Access Program stage.
2. Clinical Study Partnerships / Research Collaborations: Collaborative research studies with academic medical centers (Dana-Farber, MGH, Weill Cornell, Mount Sinai, City of Hope, Emory Winship, Sequoia Hospital/Dignity Health, John B. Amos, xCures) including the TRV-001, solid tumor, AML, TRV-002 and TRV-003 (TraveraRTGx) studies. Studies generate clinical evidence and, where samples are run through approved CLIA pipelines, CLIA reports are returned to collaborating sites (e.g., xCures patient portal).
3. No-Cost Clinical Study Access (Peritoneal and GI Cancers): Travera EarlyAccess™ is also offered through a no-cost, nationwide clinical study for certain indications (e.g., peritoneal cancers, colon/GI cancers), with additional financial assistance available. This serves as a study-driven channel to broaden access and gather evidence.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels10 records

Core offering

Travera operates a CLIA-certified clinical laboratory in Medford, Massachusetts that runs the Rapid Therapy Selection™ test, a Laboratory Developed Test (LDT) using proprietary MIT-developed Suspended Microchannel Resonator (SMR) MEMS technology to weigh live cancer cells ex vivo and predict which FDA-approved drugs or drug combinations are most likely to work for a given patient's unique cancer. The test is offered in two commercial variants — Travera EarlyAccess™ (predetermined panel of up to 20 drugs for $500, requires outcome-data sharing) and Travera RTS™ (custom panel of up to 20 drugs at $1,000 per drug) — with a 2-day turnaround from sample collection to physician report delivery.

Product overview

Travera operates a single unified clinical Laboratory Developed Test (LDT) product line — the Rapid Therapy Selection™ test — that is delivered in two commercial variants, Travera EarlyAccess™ (a predetermined panel of up to 20 FDA-approved drugs per supported cancer) and Travera RTS™ (a custom panel of up to 20 drugs from Travera's 100+ drug catalog). Both variants are powered by the company's core proprietary technology, the Suspended Microchannel Resonator (SMR) — a MEMS single-cell weighing platform invented at MIT — and run through the Travera Clinical Platform & Workflow, which combines cell purification, controlled drug incubation, SMR-based mass distribution measurement with an AI image-classification impurity-removal step, and p-value-based scoring to produce a 0–100 drug-response report in ~2 days.

Differentiator

Problem solved

Functional benefit

Brands

• Rapid Therapy Selection™: Travera's cancer therapy guidance test that evaluates FDA-approved drug options to assess their potential for treating a patient's unique cancer, with a 2-day turnaround time.
• Rapid Therapy Guidance™
• Travera EarlyAccess™
• Travera RTS™

Products and services

• Travera Rapid Therapy Selection™ Test CLIA-certified Laboratory Developed Test (LDT) that weighs live tumor cells ex vivo using the proprietary Suspended Microchannel Resonator (SMR) to predict which FDA-approved cancer drugs or drug combinations are most likely to be effective for an individual patient's cancer; delivers a scored report to the ordering physician in approximately 2 days from sample collection. Ordered by licensed oncologists; available for adult (≥18) patients with late-stage, relapsed, or treatment-refractory cancers.
• Travera EarlyAccess™ Predetermined-panel variant of the Rapid Therapy Selection test that uses a Travera-determined panel of up to 20 FDA-approved drugs per supported NCCN cancer (39 panels covering ~90% of cancers). Flat $500 fee per test; patient must share treatment outcome data with Travera. Available in the U.S. only during the 24-month Early Access Program.
• Travera RTS™ Custom-panel variant of the Rapid Therapy Selection test where the oncologist (and patient) selects up to 20 FDA-approved cancer drugs from Travera's catalog of 100+ drugs to be tested against the patient's live tumor cells. $1,000 USD per drug tested (up to ~$20,000 for a full custom panel of 20 drugs). No outcome-data sharing required. Available alongside the EarlyAccess program in the U.S.
• No-Cost Nationwide Clinical Study (Peritoneal and GI Cancers) No-cost nationwide clinical study channel offering the Travera EarlyAccess test for peritoneal and colon/GI cancer patients; eligibility assessed via Jotform or phone (781-874-0808) with additional financial assistance available.

Quantifiable outcome

• 2-day turnaround time from sample collection to test report — industry's fastest for cancer therapy guidance
• +7 more outcomes

Named customers19 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature7 records

Partnerships

39 partnerships are on record, tiered flagship / core, core and minor.

• MIT (Manalis Lab, Koch Institute for Integrative Cancer Research)flagship / coreStrategic or Co-development PartnerTravera's core Suspended Microchannel Resonator (SMR) technology was invented and developed in the Manalis Lab at MIT. Co-founders Scott Manalis (David H. Koch (1962) Professor in Engineering), Selim Olcum, Rob Kimmerling, and Mark Stevens all conducted their graduate and postdoctoral research at MIT's Koch Institute. Travera is headquartered approximately four miles from MIT in Medford, MA and maintains close research ties. The relationship underpins Travera's entire proprietary technology moat.
• Cancer CommonscoreStrategic or Co-development PartnerCancer Commons and Travera launched a partnership to provide Travera's Rapid Therapy Guidance tests to Cancer Commons' patients. Cancer Commons aggregates anonymized patient outcomes by cancer subtype; as their patients use the Travera test, the Cancer Commons database will show which drugs and cancer subtypes get the most accurate therapy guidance. Joint educational webinar co-hosted with Marty Tenenbaum (Cancer Commons founder). Initial Cancer Commons focus: brain, pancreatic, and prostate cancer, with the approach intended to span all cancers.
• xCures Inc.coreStrategic or Co-development PartnerPartnership on the TRV-003 (TraveraRTGx) 200-patient pilot study leveraging xCures' longitudinal observational research study XCELSIOR (NCT03793088). xCures manages all records collection and data entry centrally; reports are shared with xCures as study site for delivery to providers and patients via the xCURES patient portal. Site PI: Dr. Jennifer Grandis (UCSF) at xCures Decentralized Oncology Study Sites.
• METAvivorcoreGTM or Marketing PartnerPartnership to make Travera's Rapid Therapy Guidance test available to METAvivor's metastatic breast cancer patients through a special program. Includes an educational webinar and an extended interview with METAvivor Board of Directors member Janice Cowden (a metastatic breast cancer patient since 2016). Travera is referenced in METAvivor patient education materials and the collaboration focuses on moving 'the needle forward' in personalized precision treatment for metastatic breast cancer.
• Dana-Farber Cancer Institute (Dr. Nikhil Munshi, Dr. Adam Sperling, Dr. Marlise Luskin)coreImplementation/ SI/ Consulting PartnerSite for the TRV-001 (RRMM) Vanguard cohort and RRMM cohort studies and the AML pilot study with Dr. Marlise Luskin and the DFCI Acute Leukemia Group. 30 AML patient samples are obtained from peripheral blood draws or bone marrow aspirates at DFCI. Dr. Luskin is responsible for annotating patient outcomes on a regular basis post-enrollment.
• Massachusetts General Hospital (Dr. Andrew Branagan)coreImplementation/ SI/ Consulting PartnerClinical study site for the TRV-001 study in relapsed refractory multiple myeloma (RRMM). Investigates bone marrow aspirate samples from patients prior to the start of a new treatment regimen.
• Weill Cornell Medicine (Dr. Cara Rosenbaum, Dr. Ruben Niesvizky)coreImplementation/ SI/ Consulting PartnerClinical study site for the TRV-001 (RRMM) study. Bone marrow aspirate samples collected from patients prior to the start of a new treatment regimen with prospective measurements of mass response to ex vivo treatment with that same regimen.
• Mount Sinai (Dr. Sundar Jagannath)coreImplementation/ SI/ Consulting PartnerClinical study site for the TRV-001 (RRMM) study. Bone marrow aspirate samples collected from patients prior to the start of a new treatment regimen with prospective measurements of mass response to ex vivo treatment.
• City of Hope (Dr. Amrita Krishnan)coreImplementation/ SI/ Consulting PartnerClinical study site for the TRV-001 (RRMM) study. Provides bone marrow aspirate samples from patients prior to the start of a new treatment regimen for prospective measurements of mass response to ex vivo treatment with that same regimen.
• Emory Winship Cancer Institute (Dr. Ajay Nooka)coreImplementation/ SI/ Consulting PartnerClinical study site for the TRV-001 (RRMM) study. Dr. Nooka is also an investigator on the John B. Amos Cancer Center-adjacent TRV-002 study. Provides bone marrow aspirate samples for prospective mass response measurements.
• Sequoia Hospital, Dignity Health (Dr. Anobel Tamrazi)coreImplementation/ SI/ Consulting PartnerSite for the Solid Tumor Clinical Study, a sub-study of the existing 'CT-Biome' Precision Biopsy Project protocol led by Dr. Anobel Tamrazi. 150-patient feasibility study using FNAs, CORE biopsies, pleural effusions, blood samples; 77 of 150 patients enrolled. Dr. Tamrazi also serves on Travera's Sample Collection Advisory Council.
• John B. Amos Cancer Center (Dr. Andrew Pippas)minorImplementation/ SI/ Consulting PartnerSite PI for the TRV-002 130-patient pilot study. Samples will be collected from patient cohorts with breast cancer (30 pts), lung cancer (30 pts), multiple myeloma (20 pts), acute myelogenous leukemia (20 pts), and carcinoma-associated malignant fluid (30 pts). TRV-002 enrollment has not yet started.
• Dr. Sanjay Juneja (TheOncDoc) — Oncology Advisory CouncilcoreGTM or Marketing PartnerTriple board-certified Hematologist & Medical Oncologist and Chief of Oncology Service at Baton Rouge General Hospital. Serves on Travera's Oncology Advisory Council. Has 500K+ subscribers as 'TheOncDoc,' co-founded medfluencers.com (40M+ subscribers across healthcare creators), host of 'Target: Cancer' podcast, and active participant in the 2022 White House Healthcare Leaders in Social Media Roundtable. Drives significant organic social reach for Travera messaging.
• Dr. Brian Leyland-Jones — Oncology Advisory CouncilcoreGTM or Marketing PartnerPast Chief of Developmental Therapeutics at the NCI; serves on Travera's Oncology Advisory Council. Former Director of McGill University Comprehensive Cancer Center and Winship Cancer Centre at Emory. Recipient of 2021 McGill University Lifetime Achievement Award. Has coordinated international development of Paclitaxel and contributed to Herceptin development (0648g, HERA, NeoSphere). Co-founder of Xanthus Pharmaceuticals (exit to Antisoma), AKESOgen (exit to Tempus), Viviphi, Parthen, PITO. Currently CMO and Treasurer of the National Foundation for Cancer Research.
• Dr. Shayma M. Kazmi — Oncology Advisory CouncilminorGTM or Marketing PartnerMedical oncologist at University of Pennsylvania Abramson Cancer Institute; specializes in thoracic malignancies (lung, head & neck, thyroid, brain, breast cancers). Assistant Professor at Rowan Medical School. SITC podcast project lead; member of IASLC Education Committee. Serves as a consultant and subject matter expert in national and international Foundation Medicine tumor board discussions. Serves on Travera's Oncology Advisory Council.
• Dr. Reshma L. Mahtani — Oncology Advisory CouncilminorGTM or Marketing PartnerChief of Breast Medical Oncology at Miami Cancer Institute, Baptist Health South Florida (Memorial Sloan Kettering affiliate). Former Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami. Serves on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and Director of the ASCO Highlights series. Serves on Travera's Oncology Advisory Council.
• Dr. Anobel Tamrazi — Sample Collection Advisory CouncilcoreGTM or Marketing PartnerInterventional Radiologist (IR) working in the Bay Area. Stanford-trained; affiliated with Sutter Medical Network, Sequoia Hospital, Stanford, and El Camino Hospital. Specializes in image-guided IR and interventional oncology procedures with a strong interest at the intersection of image-guided tumor sampling (tissue and liquid biopsy) and tumor diagnostic testing including next-generation sequencing and functional precision oncology. Also serves as PI on the Travera Solid Tumor Clinical Study and is on the Sample Collection Advisory Council.
• Dr. Abhishek Srinivas — Sample Collection Advisory CouncilminorGTM or Marketing PartnerClinical Associate in the Division of Vascular and Interventional Radiology at Johns Hopkins University School of Medicine; practices at two hybrid academic/community hospitals in the National Capital Region and has clinical/teaching responsibilities at the Johns Hopkins Hospital main campus in Baltimore, MD. Expertise spans interventional oncology, image-guided biopsies, and locoregional therapies. Serves on Travera's Sample Collection Advisory Council.
• Scott Manalis, Ph.D. — Co-founder and Principal Consultantflagship / coreStrategic or Co-development PartnerCo-founder of Travera and the David H. Koch (1962) Professor in Engineering at MIT with faculty appointments in biological and mechanical engineering departments. Associate department head of the biological engineering department and a member of the Koch Institute for Integrative Cancer Research and MIT's Center for Precision Cancer Research. Recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE). His research group invented the SMR that powers Travera's test.
• David Margulies, M.D. — Co-founder, Strategic Advisor and Board Memberflagship / coreStrategic or Co-development PartnerCo-founder of Travera and member of the Board of Directors since 2018. Founded/co-founded and served as Director/Senior Executive at BRS Medical (acquired by WB Saunders/Elsevier North Holland), CIO at Boston Children's Hospital, EVP/Chief Scientist/BOD member at Cerner, CareInsite (acquired by WebMD), Correlagen Diagnostics (acquired by LabCorp), and Q-State Biosciences. BA from Amherst College; MD from Harvard Medical School. Provides strategic guidance on company direction and commercialization.
• Mark Stevens, PhD — Co-founder and Executive Consultantflagship / coreStrategic or Co-development PartnerExecutive Consultant and co-founder of Travera. Joined from Dana-Farber Cancer Institute, where as a research scientist he led a team working on the development of the MAR biomarker platform across malignancies. Previously served as VP of Clinical Development and interim-CEO at Travera. PhD in Biology from MIT's Koch Institute for Integrative Cancer Research.
• Keith Ligon, M.D., Ph.D. — Scientific AdvisorminorStrategic or Co-development PartnerPhysician-Scientist with expertise in neuropathology and oncology-focused on improving the diagnosis and treatment of cancer. Associate Professor of Pathology at Harvard Medical School with joint appointments at Dana-Farber Cancer Institute, Broad Institute, and Brigham and Women's Hospital. Chief of Neuropathology at BWH/DFCI; Director of the Center for Patient-Derived Models (CPDM) at DFCI. Serves on Travera's Advisory Team.
• Steve Wasserman — Consultant (MIT bioinstrumentation)minorStrategic or Co-development PartnerSenior lecturer in the Biological Engineering Department at MIT, teaching hands-on bioinstrumentation lab courses (20.309 and 20.345). Also Consulting Director of Engineering at Q-State Biosciences; develops instruments for academic and industrial labs. Previously worked at Apple, Microsoft, WebTV, and 3DO. Serves on Travera's Advisory Team and contributes engineering/development expertise.
• FedExcoreOthersOperative logistics partner for sample shipment. Once collected, samples must be immediately placed in the provided temperature-controlled shipping kit and delivered to FedEx according to the provided instructions. Travera receives samples within 24 hours of collection. No shipments on Saturdays or Sundays (lab is closed Sundays and Mondays).
• Free ME from Lung CancerminorGTM or Marketing PartnerCommunity organization dedicated to raising money for lung cancer research, education, advocacy, and community support. Listed Travera community partner.
• No Stomach for CancerminorGTM or Marketing PartnerPatient advocacy organization advancing awareness and education about stomach cancer. Listed Travera community partner.
• The Chrysalis InitiativeminorGTM or Marketing PartnerOrganization working to disrupt outcome disparities within breast cancer so every patient receives the care they deserve. Listed Travera community partner.
• SpeciCareminorGTM or Marketing PartnerCompany revolutionizing cancer research, clinical care and pharma industries to give patients their best chance at survival. Listed Travera community partner.
• Norma Leah Ovarian Cancer InitiativeminorGTM or Marketing PartnerOffers early detection education, patient support services, and research funding for ovarian cancer. Listed Travera community partner.
• Blue FaeryminorGTM or Marketing PartnerMission to prevent, treat, and cure primary liver cancer through research, education, and advocacy. Listed Travera community partner.
• Colorectal Cancer AllianceminorGTM or Marketing PartnerLeads scientific efforts to defeat colorectal cancer and inspires progress to save lives. Listed Travera community partner.
• Manta CaresminorGTM or Marketing PartnerCreates tools and resources to help make the cancer experience just a little easier. Listed Travera community partner.
• Pancreatic Cancer Action Network (PanCAN)minorGTM or Marketing PartnerVision to create a world in which all patients with pancreatic cancer will thrive. Listed Travera community partner.
• Cancer Help DeskminorGTM or Marketing PartnerOffers personalized education, resources, and treatment choices to anyone dealing with cancer. Listed Travera community partner.
• Twisted PinkminorGTM or Marketing PartnerLeads efforts to provide better access to care for people living with metastatic breast cancer. Listed Travera community partner.
• Hope for Stomach CancerminorGTM or Marketing PartnerEnables those affected by stomach cancer to take actionable steps and live the best possible life. Listed Travera community partner.
• Down There AwareminorGTM or Marketing PartnerSheds light on gynecologic cancer and advocates for women everywhere; co-produced a podcast with Travera (Cliff Reid and Dennis Watson). Listed Travera community partner.
• GO2 for Lung CancerminorGTM or Marketing PartnerAt the forefront of everything happening in lung cancer. Listed Travera community partner.
• Genetic AllianceminorGTM or Marketing PartnerNon-profit leader in deploying high tech and high touch programs for individuals, families, and communities. Listed Travera community partner.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Guardant Health: Established liquid biopsy leader with FDA-approved Guardant360 CDx for comprehensive genomic profiling in advanced cancer. While primarily genomics-based, Guardant competes for the same oncologist therapeutic decision-making workflow that Travera targets with its functional mass-response test.
• Caris Life Sciences: Established molecular profiling incumbent offering comprehensive genomic, transcriptomic, and now functional profiling (Caris Assure, MI Profile) for oncology therapy selection. Competes with Travera in cancer therapy guidance but operates as a broad multi-omics platform with substantially larger commercial reach and reimbursement infrastructure.
• Personalis: Molecular diagnostics company with a strong oncology focus, providing tumor profiling and ctDNA/MRD testing (NeXT Personal). Personalis overlaps with Travera in the precision oncology space, serving oncologists seeking molecular guidance on therapy selection, though it is genomics-centric rather than functional.
• Tempus: Broad molecular profiling incumbent offering NGS-based oncology testing, AI-enabled diagnostics, and increasingly functional assay capabilities. Tempus serves the same oncologist customer base as Travera and is actively expanding into functional precision oncology, representing both a partner and a competitive threat.
• Agendia: Oncology molecular diagnostics company best known for MammaPrint and BluePrint breast cancer assays. Agendia shares Travera's oncology-focused diagnostics positioning, has established commercial sales force, and is led by executives who overlap with Travera's VP Business Development Dennis Watson's prior tenure — a comparable oncology Dx commercial model.

Emerging players

• Strata Oncology: Precision oncology company providing tumor molecular profiling (StrataNGS) and a clinical trial matching platform for advanced cancer patients. Strata overlaps with Travera in serving oncologists treating late-stage patients who have exhausted standard-of-care options, though it is primarily genomics-based rather than functional.
• xCures: Decentralized precision oncology platform (XCELSIOR observational study, NCT03793088) that is a current Travera clinical research partner on TRV-003. xCures aggregates treatment outcomes to support therapy selection for late-stage patients — overlapping in mission and end-customer (advanced cancer patients seeking personalized therapy), making it both a partner and an adjacent peer.

Direct peers

• Champions Oncology: Functional precision oncology peer offering ex vivo patient-derived xenograft (PDX) and tumor fragment drug response testing services to oncologists and pharma. Champions' approach overlaps with Travera's in using live patient tissue to predict drug response, and they share the same target market of late-stage cancer patients seeking personalized treatment options.
• Notable Labs: Direct peer in functional precision oncology, focused on ex vivo drug sensitivity testing to identify effective cancer therapies for individual patients. Notable Labs targets the same late-stage, treatment-refractory patient population and uses predictive biomarker approaches analogous to Travera's Mass Response biomarker.
• Kiyatec: Direct competitor in functional precision oncology. Kiyatec offers ex vivo 3D cell culture drug response assays (KIYA-Predict) for glioma and other solid tumors, with the same goal of predicting patient-specific drug response from live tumor cells — directly comparable in technology approach and clinical positioning to Travera's SMR-based RTS test.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Travera